PharmaTalkRadio

Summary: This session was recorded at the March 2025 Patients as Partners conference. In this session, Pfizer addressed how they were working to ensure continuity in the patient insights they were collecting, throughout the product life cycle. This included: Approaches for aligning internal processes to facilitate the seamless flow of patient insights from early-phase to late-phase teamsSuggested tools, including an AI Insights tool designed to centralize and leverage previous patient feedback, supporting a more integrated approach to patient engagementStrategies to build on existing insights, enhance collaboration across teams, and drive more effective patient-centered outcomes in R&D processesFor more information, go to PatientsAsPartnersConference.com.

Summary: From the DPHARM Archives, this podcast was recorded at the September 2024 DPHARM conference. In this podcast, BMS present how they specifically targeted the challenge of recruiting patients for clinical trials, aiming to make the process faster and easier. By bringing trials directly to patients, their ultimate objective was to significantly expedite patient enrollment. In this case example, they brought the audience through their new product model approach, for the organization's overarching goal of reducing the drug timeline from discovery to launch by three years.

About this podcast:Recorded at the 2025 Immuno-Oncology 360º Summit, Stanford University's Dr Crystal Mackall shares work from her lab developing GD2-targeting CAR T cell therapy for the treatment of deadly pediatric brain tumor, as well as broader lessons on the evolution of cell therapy, and her forward-looking perspective on shaping the next generation of cancer treatments.For more information, go to IO360summit.com. 

Summary:Rescuing a clinical trial and choosing to switch vendor's mid-trial are some of the most expensive decisions biotech CMOs can make. These rescues require a significant amount of time, money and energy and may not even address the root issue behind a trial's poor performance. In this podcast, Raul Lima, SVP, Strategic Clinical Operations, inSeption Group, discusses a scaffolding approach that prioritizes areas that require immediate support without sacrificing the entirety of the trial. Specifically:How biotechs can better identify root causes of issues and correct themMistakes CMOs make when implementing rescuesWhen and how a scaffolding approach can be more resource, time and financially efficientFor more information about inSeption Group, visit inSeptionGroup.com. For more information about the annual Chief Medical Officer Summit 360° and its affiliated editorials, podcasts and webcasts, please visit CMO360.org.

Summary:When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kymanox discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically:Impact on increasing concentration of drugs on deliverabilityTechnical feasibility of manufacturing larger volume devicesPatient tolerability and human factors that impact patient adherenceThis panel discussion was recorded at the October 2024 PODD: Partnership Opportunities in Drug Delivery conference. For more information, go to Drug-Delivery.org.

In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part III of this podcast series covers sessions addressing AI in Clinical Trials.

Summary:Accessibility to CAR-T is limited by traditional manufacturing, with its associated challenges and high cost. Moffitt Cancer Center's Chief BioEngineering Officer, Dr Greg Sawyer, highlights Moffitt's significant progress in enhancing T cell potency and boosting efficacy through engineering strategies. Dr Sawyer discusses assays enabling precise asessment of T cell potency, developments in manufacturing, and more, and the resulting impact on scalability and efficiency. This presentation comes from the March 2025 Immuno-Oncology 360º Summit. For more information, go to IO360summit.com. 

Summary:In this podcast, Pharma and Drug Delivery executives from Novartis, AstraZeneca, Merck and Quotient Sciences discuss traditional and novel approaches to improve the oral delivery of peptides including:The biopharmaceutics of oral peptide and the use of permeation enhancersAlternate sites for the delivery of oral peptides throughout the GI tractImproving oral exposure through ingestible devices Delivering ASOs and other large syntheticsNext-generation approaches for deliveryThis presentation was recorded at the October 2024 PODD: Partnership Opportunities in Drug Delivery conference. For more information, go to Drug-Delivery.org.

Summary: In this podcast, Dr Anthony Yanni, SVP, Head of Patient Centricity at Astellas, presented the business rationale for patient-centric medicine development, how it's disrupting the pharmaceutical industry and why companies have to act swiftly to remain competitive. Dr Yanni discusses how to align medicine development with healthcare delivery and the necessary cultural transformation that is critical to sustaining it, practical steps to incorporate patient input early into the R&D process, operationalizing patient-centric processes, methods to measure impact, and more.This presentation was recorded at the March 2025 Patients as Partners in Clinical Research conference. For more information, go to PatientsAsPartnersConference.com.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs across indications about how CMOs can better develop drugs patients want and derisk development by partnering with patient organizations. Specifically, the panelists address:Patient voice driving drug development forwardSupporting health equity and patient access after approvalBuilding genuine relationships and engaging early to get to the right patients at the right time and for better advocacy about your researchBuilding a community of awareness and working with patients for support throughout the regulatory processIntegrating the patient perspective in earlyReal world examples and their impactsTo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

Summary:In this session, pharma sponsors and sites gather to present innovative solutions to solve site challenges in workforce and capability gaps, increasing technology burden, patient enrollment and managing clinical trial protocol complexity. They discuss efforts to address those challenges, early impacts and outcomes. In this panel: Dennis Salotti, MS, MBA, Executive Director & Head of Clinical Outsourcing & Innovation, Jazz PharmaceuticalsKristin Herman, Executive Director, Clinical Trials Office, Sidney Kimmel Cancer Center, Jefferson HealthEileen Hughes, RN, BS, Senior Manager, Site Partnerships, CSL BehringLisa Kiehne, SVP, Operations, The START Center for Cancer Research Christopher McNair, PhD, Associate Director, Data Science and Cancer Informatics, Sidney Kimmel Cancer Center, Jefferson HealthTracey Robertson, Head of Patient and Site Engagement Capability Management, Boehringer Ingelheim This panel was recorded at the 2024 DPHARM: Disruptive Innovations to Advance Clinical Research. For more information about the 2025 DPHARM, visit DPHARMconference.com.

Conference Forum Director Valerie Bowling and CRAACO Producer Danny McCarthy break down what to expect at the 2025 CRAACO program. This podcast covers the keynotes, panels and key themes for this year's event, including: How to develop a clinical research program within a community cancer center, with Dr Brian Slomovitz, Mount Sinai Medical Center Miami BeachTurning clinical environments into learning health systems, with Dr Laura Esserman, UCSF Carol Franc Buck Breast Cancer CenterHow to better partner with multiple location health system structures for clinical trials Addressing medical staff shortages and challenges to support clinical researchThe impact of clinical trial participation on cost and performance in cancer centersEHR and AI advancements for clinical research And more Want to know more about CRAACO? Visit CRAACOevent.com.

PODD: Partnership Opportunities in Drug Delivery Directors Valerie Bowling and Andrew Goldstein break down what to expect at PODD 2025. This podcast covers keynotes and key themes for this year's event, including:Regeneron Co-Founder and CSO, Dr George YancopoulosNovo Nordisk Chief Scientific Advisor, Dr Lotte Bjerre KnudsenMIT's Robert LangerPatient Keynote, Jimi OlaghereNortheastern University's Dr Mansoor AmijiDrug Delivery Technology Presentation TracksNetworking Opportunitiesand moreWant to know more about PODD? Check it out at PODDConference.com.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs across indications about how CMOs can best support their regulatory teams and engage with the FDA and other regulators. Specifically, the panelists address:Engaging with the FDA on a peer-to-peer levelEffectively negotiating about innovative approaches that may be outside of guidelinesHow to react and respond to feedback and questions from the FDATo learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

This podcast features a panel discussion from the 2024 PODD Conference with biopharma leaders about biomaterial approaches to develop implants that can deliver molecules and optimize for dose frequency. Specifically:Defining biocompatible materials and biomaterialsDifferences between small and larger moleculesBenefits and challenges of implantsTo learn more about the PODD conference, please visit Drug-Delivery.org.

Summary:The consolidation of independent clinical trial sites into larger, integrated networks represents a strategic evolution in clinical research. This panel from the 2024 DPHARM conference discusses whether or not this level of consolidation can bring new researchers and new sites into clinical research, and lead to reduced risk to sponsors, increased predictability, streamlined site operations and greater access for patients. More specifically, this panel focuses on: What is the true value of site networks?What does the landscape look like today – by TA/country / region?If scaled, what will the benefit look like for patients and can it impact the speed of treatment to patients?Case examples of the impact of current clinical research networksIn this panel:Mark Travers, PhD, MBA, VP, Head of GCTO Regions, Monitoring Excellence, Global Operations and eTMF, MerckPaul Evans, President and CEO, Velocity Clinical ResearchMark Scullion, MBA, CEO, Atlas Clinical ResearchNick Slack, MBE, Chairman and CEO, The START Center for Cancer ResearchFor more information, go to DPHARMconference.com. 

Summary:Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO. More specifically:The current tailwinds working for and headwinds working against investment in biotechThe increasing specialization of investors and lack of generalist investors The impacts of challenging and/or disappointing readouts after the first wave of checkpoint inhibitorsWhere investors are more positive on biotech, and reasons for optimism in coming pipelinesFor more information, visit IO360summit.com 

In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part II of this podcast series covers the 16 Pharma from the Trenches track case studies.

In this podcast series, DPHARM Directors Tracey Kimball and Valerie Bowling break down what to expect at DPHARM 2025. Part I of this podcast series covers keynotes and key topics for this year's event, including:Former Merck CEO, Ken FrazierFormer Head of FDA, Scott GottliebCRISPR Gene Therapy Patient Keynote, Victoria GrayTuft's Ken GetzHow DPHARM is tackling AIWhat to do about Protocol Complexityand moreWant to know more about DPHARM? Check it out at DPHARMconference.com.

About this podcast: Partnerships between industry and patient advocacy groups supply medicine development with critical patient expertise, insights and experience  on the journey towards greater patient centricity. This podcast focuses specifically on the role of patient advocacy groups in medicine development in providing a direct, and often untapped, resource for patient insights, community connections and protocol feedback. Dr Matthew Reaney, Scientific Lead, Patient-Centered Solutions at IQVIA, speaks with Trish Davidson, Senior Consultant at the Tufts Center for the Study of Drug Development and Director, PALADIN Consortium about the role of patient advocacy groups in medicine development and how PALADIN is connecting industry stakeholders to reduce duplicative efforts in patient engagement resources and advance more efficient patient engagement across the industry.In the podcast, Matt touches upon IQVIA's recent collection of perspectives from researchers, approvers and patients. The book, Patient-centricity in the Biopharmaceutical Industry: Are We Nearly There Yet? was collated and edited by Matt and gathers diverse insights on patient-centric intervention development. In formats ranging from poetry to short fiction and personal narratives to more traditional reviews of the research, 30+ contributors across the industry discuss how to be truly “patient centric.” It can be accessed for free at https://bit.ly/PatientCentricityBook. For more information on PharmaTalk Radio podcasts, you can visit theconferenceforum.org.